Art Unit 1615
Preliminary Amendment with RCE

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present

Listing of Claims:

application.

1. (Currently Amended) A sustained-release preparation which comprises:

a drug having a molecular weight of about 10,000 or less; and

a gelatin hydrogel,

wherein the drug is impregnated into said gelatin hydrogel through a surface thereof and

is maintained immobilized in said hydrogel by physiochemical interaction, and

said hydrogel having wherein a concentration gradient of the drug-is formed in the

hydrogel, such that said concentration gradient being higher at said surface than in other parts of said hydrogel in said sustained-release preparation, and the drug is immobilized within said

hydrogel by said physiochemical interaction, and

said sustained-release preparation is sterile.

2. (Canceled)

3. (Currently Amended) A method of sustained release of a drug in vivo comprising:

administering a sustained-release preparation to a patient in need thereof, said preparation comprising a drug <u>having a molecular weight of about 10,000 or less</u> and a gelatin hydrogel,

wherein said hydrogel has a concentration gradient of the drug is formed in the hydrogel, in said

Docket No.: 3691-0122PUS1

sustained-release preparation, wherein degradation of the gelatin hydrogel in vivo causes more

Docket No.: 3691-0122PUS1

drug to be released from a region with higher drug concentration, thereby giving said sustained

release of the drug, wherein the drug is impregnated into said gelatin hydrogel through a surface

thereof and is maintained immobilized in said hydrogel by physiochemical interaction, said

concentration gradient being higher at said surface than in other parts of said hydrogel, and said

concentration gradient being inguer at said surface than in other parts of said hydroger, and said

sustained-release preparation is sterile.

4. (Previously Presented) The method of claim 3, where said administration is topical.

5. (Previously Presented) The sustained-release preparation of claim 1, wherein the drug

is impregnated into said gelatin hydrogel by ionic bonding.

6. (Previously Presented) The sustained-release preparation of claim 1, wherein the

preparation is in solid or semi-solid form.

7. (New) A sustained-release preparation which comprises:

a drug having a molecular weight of about 10,000 or less; and

a crosslinked gelatin hydrogel,

said sustained-release preparation being made by adding an aqueous solution of said drug

dropwise to said crosslinked gelatin hydrogel, thereby impregnating said drug into said

crosslinked gelatin hydrogel through a surface thereof, immobilizing said drug in said

crosslinked gelatin hydrogel by physiochemical interaction between said drug and crosslinked

3 of 14 GMM/ETP/

gelatin hydrogel, and forming a concentration gradient of the drug in the crosslinked gelatin

Docket No.: 3691-0122PUS1

hydrogel such that said concentration gradient is higher at said surface than in other parts of said

hydrogel in said sustained-release preparation, wherein the amount of aqueous solution being

added dropwise causes swelling of the crosslinked gelatin hydrogel and wherein said sustained-

release preparation is sterile.

8. (New) The sustained-release preparation of claim 1, wherein said drug is an antitumor

agent.

9. (New) The method of claim 3, wherein said drug is an antitumor agent.

10. (New) The sustained-release preparation of claim 7, wherein said drug is an antitumor

agent.

GMM/ETP/